Chandler Robinson Chief Executive Officer Monopar Therapeutics LLC 598 Rockefeller Road Lake Forest, IL USA 60045 Cancer Research UK Angel Building 407 St John Street London EClV 4AD United Kingdom
Xxxxxxxx
Xxxxxxxx Chief Executive Officer
Monopar
Therapeutics LLC 000 Xxxxxxxxxxx Xxxx
Lake
Forest, IL USA 60045
Cancer Research UK
Angel Building 000 Xx Xxxx Xxxxxx Xxxxxx
XXxX
0XX Xxxxxx Xxxxxxx
020
7242 0200
xxxx.xxx
2ist March
2018
Dear
Xxxxxxxx,
Clinical Xxx.xx and Option Agreement between
Monopar Therapeutics LLC, Cancer Research UK and Cancer Research
Technology Limited dated 15th May 2015 ("the Agreement")
As
part of a recent portfolio reprioritisation, Cancer Research UK and
Cancer Research Technology have decided to close the project Which
is the subject of the Agreement. We will be working with Monopar
Therapeutics over the coming months to formalise the arrangements
necessary to effect termination of the Agreement.
Yours
faithfully,
/s/
Xxxxx Xxxxxxxxx
Xxxxx
Xxxxxxxxx
Director
of Drug Development CRUK Centre for Drug Development
Patron Her Majesty
The Queen
Presidents HRH The Duke of Gloucester KG GCVO and HRH
Princess Xxxxxxxxx, the
Hon Xxxx Xxxxxx KG
GCVO Chief Executive Xxx
Xxxxxx X Xxxxx
Regist ered
Charity in England
and Wales (1089464),
Scotland (SC041666) and the Isle
of Man (1103)
Regi stered
Company limited by guarantee in England
and Wales (4325234)
and registered rn the Isle of
Man (5713F) Registered Address Angel Building, 000 Xx Xxxx
Xxxxxx, Xxxxxx
XX0X· 4AD
